Apollomics Inc. (APLM)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-01-31 Phase2 Readout —

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT03175224 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors PHASE2 Recruiting 497
NCT04743505 Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small C... PHASE2 Active Not Recruiting 27

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for APLM.

SEC EDGAR Filings

All SEC filings for Apollomics Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.